 The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2HIF-1αVP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels a process called angiogenesis in an attempt to improve the flow of blood in the legs of patients with peripheral arterial disease PAD. 